Universitätsmedizin Göttingen

Running trials

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

  2024-512340-32-01· Phase 3· Novartis Pharma AG· Source

• Not yet recruiting

  Post-intervention dual antiplatelet therapy for mild stroke

  2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Not yet recruiting

  Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

  NCT07858123· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Recruiting

  A Study to evaluate effect of AZD6234 in adult participants with Type 2 Diabetes Mellitus and obesity or overweight

  2025-524616-11-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

  NCT07473128· Phase 3· Pharmacosmos A/S· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  Phase 2 Trial of TAK-755 for Acute Ischemic Stroke

  2025-522734-31-00· Phase 2· Takeda Development Center Americas Inc.· Source

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· AstraZeneca· Source

• Recruiting

  A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.

  2025-524488-18-00· Phase 2· Astellas Pharma Global Development Inc.· Source

• Recruiting

  A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluate the efficacy and safety of QVM149 (indacaterol acetate / glycopyrronium bromide / mometasone furoate) compared to salmeterol xinafoate/fluticasone propionate in children from 12 years to less than 18 years of age with asthma.

  2022-502365-26-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  NCT07784725· Phase 3· AstraZeneca· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07711418· Phase 3· Nektar Therapeutics· Source

• Recruiting

  The RAPID-Elapse study: Can the drug bupropion improve fatigue symptoms in patients with long COVID?

  2025-524443-12-00· Phase 2· Goethe University Frankfurt· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Dr. Andreas Ziegler· Source

• Recruiting

  ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

  NCT07673627· Phase 2· argenx· Source

• Not yet recruiting

  Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?

  2026-525513-31-00· Phase 3· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

  NCT07333066· Phase 3· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Recruiting

  A Study of TAK-755 in Adults With Acute Ischemic Stroke

  NCT07392450· Phase 2· Takeda· Source

• Recruiting

  Pembro-FLASH

  NCT06045159· Phase 2· University Of Cologne· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Philipps University Marburg· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Active, not recruiting

  A study to learn about how well BAY 3401016 works in adults with Alport syndrome

  2024-516471-33-00· Phase 2· Bayer AG· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

  NCT07294170· argenx· Source

• Recruiting

  ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

  NCT07284420· Phase 2· argenx· Source

• Recruiting

  Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma

  2022-500676-59-00· Phase 2· GPOH gGmbH· Source

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· University of Cologne· Source

• Recruiting

  SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

  NCT06804161· Phase 3· Prof. Dr. med. Ingo Eitel· Source

• Recruiting

  Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

  NCT07038356· Phase 3· Christian Schulze· Source

• Recruiting

  A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

  2024-515125-28-00· Phase 2· Imbria Pharmaceuticals Inc.· Source

• Not yet recruiting

  A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stage of Alzheimer's disease

  2022-501137-23-00· Phase 2· Immungenetics AG· Source

• Recruiting

  Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.

  2024-516906-47-00· Phase 2/3· Daiichi Sankyo Inc.· Source

• Recruiting

  A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

  NCT06847542· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

  NCT07227402· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

  NCT07160608· Phase 2· Alexion Pharmaceuticals, Inc.· Source

• Recruiting

  PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA

  2024-512922-27-00· Phase 2· Klinikum der Universitaet Muenchen AöR· Source

• Recruiting

  Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma

  NCT07260175· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Recruiting

  Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

  NCT07007065· Phase 3· AbbVie· Source

• Recruiting

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· Phase 2· Universität Münster· Source

Showing 50 of 223.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers19 recruiting
• Lung cancer12 recruiting
• Heart failure10 recruiting
• Stroke8 recruiting
• Myasthenia gravis7 recruiting
• Colorectal cancer6 recruiting
• Sarcoma6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Alzheimer disease5 recruiting
• Liver and biliary tract cancer5 recruiting
• Macular degeneration5 recruiting
• Coronary artery disease4 recruiting
• Dermatomyositis and polymyositis (myositis)4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Prostate cancer4 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Chronic kidney disease3 recruiting
• Follicular lymphoma3 recruiting
• Immune thrombocytopenia (ITP)3 recruiting
• Obesity3 recruiting
• Pancreatic cancer3 recruiting
• Asthma2 recruiting
• Atrial fibrillation2 recruiting
• Bladder cancer2 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)2 recruiting
• Duchenne muscular dystrophy2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Hearing loss2 recruiting
• High blood pressure2 recruiting
• Hypertrophic cardiomyopathy2 recruiting
• Mantle cell lymphoma2 recruiting
• Melanoma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Parkinson disease2 recruiting
• Retinitis pigmentosa2 recruiting
• Type 2 diabetes2 recruiting
• Acute myeloid leukaemia1 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Brain aneurysm1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Hidradenitis suppurativa1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Kidney cancer1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Multiple system atrophy1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Ovarian cancer1 recruiting
• Polycystic kidney disease1 recruiting
• Schizophrenia1 recruiting
• Type 1 diabetes1 recruiting
• Vascular dementia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Withdrawn

  Confirmatory Study of Govorestat in CMT-SORD

  NCT07191912· Phase 3· Applied Therapeutics, Inc.· Source

• Completed

  Improving Dental Care for Patients With Head and Neck Tumors

  NCT07328347· University Medical Center Goettingen· Source

• Completed

  A Study Evaluating BFB759 in Atopic Dermatitis

  2025-521624-30-00· Phase 2· Bluefin Biomedicine Inc.· Source

• Completed

  Facilitators and Barriers to Dental Care in Head and Neck Cancer Patients

  NCT06559384· University Medical Center Goettingen· Source

• Completed

  CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3

  NCT04524208· Phase 2· Universitaetsmedizin Goettingen· Source

• Completed

  Cognitive Function, Depression, Anxiety, and Quality of Life in Chronic Heart Failure Patients with Iron Deficiency with and without Anaemia: Effects of Intravenous Iron (Ferric Derisomaltose) CogFer-HF Study

  2024-515046-17-00· Phase 4· Universitaetsmedizin Goettingen· Source

• Completed

  Study to assess the safety, pharmacokinetics and efficacy of HMPL-523 in patients with Immune Thrombocytopenia

  2023-508819-23-00· Phase 1· Hutchmed Ltd.· Source

• Completed

  Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome (REVIVE)

  2024-511628-16-00· Phase 2· Goethe University Frankfurt· Source

• Completed

  SpinChip Hs-cTnI Clinical Diagnostic Performance

  NCT06499519· SpinChip Diagnostics ASA· Source

• Completed

  A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

  NCT06431763· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

  NCT06384547· Phase 3· Viridian Therapeutics, Inc.· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· University of Heidelberg Medical Center· Source

• Withdrawn

  A Study of Macitentan in Children Below 2 Years of Age

  NCT05731492· Phase 1· Actelion· Source

• Completed

  Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)

  NCT06122961· Novo Nordisk A/S· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

  NCT06021054· Phase 3· Viridian Therapeutics, Inc.· Source

• Terminated

  Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients

  NCT06050434· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Almirall S.A.· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Cytokinetics· Source

• Completed

  A Phase 2 Study of the Effects of Ponsegromab on Health-Related Quality of Life and Safety in Patients With Heart Failure (GARDEN-TIMI 74)

  NCT05492500· Phase 2· Pfizer Inc.· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Cardiomyopathy

  NCT05582395· Phase 3· Myokardia Inc.· Source

• Terminated

  Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

  NCT05570409· Phase 2/3· LMU Klinikum· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Completed

  A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)

  2024-512451-20-00· Phase 2/3· Klinikum der Universitaet Muenchen AöR· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

  NCT05620836· Phase 3· Incyte Corporation· Source

• Completed

  A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05724199· Phase 3· Amgen· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Terminated

  Prednisolone Versus Colchicine for Acute Gout in Primary Care

  NCT05698680· Phase 4· University Medicine Greifswald· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Completed

  A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

  NCT05176639· Phase 3· Viridian Therapeutics, Inc.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

  NCT05239169· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

  NCT05101629· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Amgen· Source

• Completed

  Study to understand if inclisiran is better than a placebo at lowering LDL-cholesterol,is safe and can have an impact on patient quality of life, when given along with other lipid lowering medications.

  2024-511263-28-00· Phase 4· Novartis Pharma AG· Source

• Completed

  Effect of antifibrotic therapy on regression of myocardial fibrosis after transcatheter aortic valve implantation (TAVI) in aortic stenosis patients with high fibrotic burden

  2024-510869-42-00· Phase 2· Universitaetsmedizin Goettingen· Source

• Completed

  A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

  NCT04773782· Phase 1/2· Blueprint Medicines Corporation· Source

• Completed

  Tiotropium in preventing preschool asthma (TIPP)

  2024-513916-84-00· Phase 3· Goethe University Frankfurt· Source

• Active, not recruiting

  D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

  NCT05212012· Phase 1/2· AIO-Studien-gGmbH· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

  NCT04903197· Phase 1· Novartis Pharma AG· Source

• Completed

  Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment (PACE-Lung)

  2024-517965-18-00· Phase 2· Goethe University Frankfurt· Source

• Completed

  A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration

  NCT04757610· Phase 3· Opthea Limited· Source

Showing 50 of 90.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease115 works · 9 trials
• Parkinson disease71 works · 2 trials
• Atrial fibrillation48 works · 3 trials
• Multiple sclerosis32 works · 2 trials
• Lewy body dementia14 works · 0 trials
• Myasthenia gravis13 works · 9 trials
• Dilated cardiomyopathy13 works · 1 trial
• Aortic stenosis12 works · 4 trials
• ALS (motor neurone disease)12 works · 0 trials
• Long COVID and ME/CFS10 works · 2 trials
• Frontotemporal dementia9 works · 0 trials
• Neuromyelitis optica (NMOSD)9 works · 0 trials
• Hydrocephalus7 works · 0 trials
• Brain aneurysm6 works · 1 trial
• Retinitis pigmentosa5 works · 2 trials
• Duchenne muscular dystrophy5 works · 2 trials
• Multiple system atrophy5 works · 1 trial